Last Price | 143.85 | Max Price | 166.99 |
Min Price | 143.85 | 1 Year return | -18.57 |
Sector | Health Care | Subsector | Pharmaceuticals |
Annual report 2020 |
Johnson & Johnson
Johnson & Johnson is the global leading firm for carrying out the processes of manufacturing and sales of medical, health care, and pharmaceutical products for consumers and to fulfill the needs of research and developmental activities on a broader range of health care fields. The company has been founded back to the year in 1886 by Robert Wood Johnson, James Wood Johnson and Edward Mead Johnson and has been head-quartered in New Brunswick, New Jersey and the consumer-division is being headed in Skillman, New Jersey. The company has been assisted with the help of around 250 auxiliary units which operates in about 57 of the countries worldwide and the selling of its productions is being done in 175 of the countries. In the year of 2011, this company had acquired a sales reach up to 65 Billion $ in the field of pharmaceuticals and is now trade with the help of the New York Stock Exchange and is one of the main component of Dow Jones Industrial Average and also of S&P 500 Component. Fortune 500 has also given the space to Johnson & Johnson in its listings along with the top rank of Harris Interactive National Corporate Reputation Survey and the tag of ‘world's most respected company’ by Barron’s Magazine and at last had been given the award of Benjamin Franklin for the ‘Public Diplomacy by the U.S. State Department’, the first award given to any of the Corporation.
ALZA Corporation, LifeScan, Inc., McNeil Nutritionals, Biosense Webster, Inc., Cilag, Cordis Corporation, Janssen Pharmaceutica, Penaten, Tibotec and many more names are included in the list of the auxiliaries of this company. And for naming the brands acquired by this company, there are also a fewer examples starting from the house-hold name for medical and first-aid purpose products i.e. BandAid, Tylenol, Johnson's baby products, Neutrogena skin and beauty products, Clean & Clear facial wash, Acuvue, Cortef, Reactine, Motrin, Benadryl, Calprofen, Simponi, and the list is not completed yet.
There are three of the main division that have been made by this company and those includes Consumer, Pharmaceutical and Medical Devices & Diagnostics. Consumer division take care of broader ranges of consumer-health and personal-care productions that may be of baby, beauty, oral-care, women health category or related to nutrition. Pharmaceutical division is for focusing of medical needs that have not been fulfilled yet including the therapeutical treatment of immunology, neuro-science, cardio-vascular, oncology or that of metabolism. Medical Devices & Diagnostics divisions go for broader ranges of services and products with the distribution to the whole-salers, retailing entities, hospitals, clinics and other diagnostic labs where these products are used for the researches and treatments by physician, nurses and therapists. The main focus of this section includes the cardio-vascular diseases, diabetic care, visionary care, wound-care, preventing of infectious materials, invasive surgeries (minimal type) and for diagnosis.
Contact info:Street: One Johnson & Johnson PlazaZip Code: P.O. Box 767Postbox: New Jersey 08933City: MilwaukeeCountry: USAPhone: (732) 524-0400Website: www.jnj.comCEO: Alex Gorsky
Year | Turnover | Total sector | Market share |
---|---|---|---|
2019 | 82,059 | 615,670 | 13.33 % |
2020 | 82,584 | 638,104 | 12.94 % |
2021 | 93,775 | 727,997 | 12.88 % |
2022 | 94,943 | 787,317 | 12.06 % |
2023 | 0 | 0 | 0.00 % |
2023 record year for Johnson & Johnson
Johnson & Johnson given go-ahead for bankruptcy strategy on talc lawsuits
Johnson & Johnson unit, SRI International to collaborate on drug discovery using AI
J&J Janssen unit, SRI International to collaborate on drug discovery using AI
J&J expects to file for 14 new drugs by 2025
2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|
Johnson & Johnson's main office is based in Milwaukee. The company mostly operates in the health care eq. & services sector. Alex Gorsky is the company' CEO. Over the past 10 years the global health care companies gained around 102 percent. Measured since 2011 the sector is 64 percent higher and over the past 12 months (December 2015-2016) there is a plus of 102 percent.
The period between December 2015 and December 2016 was a profitable period for the investors in Johnson & Johnson. The stock gained around 13 percent. The period between August 2011 and August 2016 was a good period for the investors. The stock rose around 77 percent. Johnson & Johnson's revenues between 2011 and 2015 were relatively stable and moved between 41,96 billion dollars and 37,18 billion dollars. Johnson & Johnson's net incomes between 2011 and 2015 were quiet stable and moved between 1,74 billion dollars and 1,55 billion dollars.
Johnson & Johnson paid out dividends in the past 5 years. Over the past 5 years the stock delivered an average dividend return of 4,04 percent. Over the past 5 years Johnson & Johnson raised her dividends share each year. Because of the yearly increased dividends Johnson & Johnson can be called a kind of dividend aristocrat.
At the end of 2015 around 126,5 thousand people were employed at Johnson & Johnson.
As per the end of 2015 the American company's balance sheet equaled 29,67 billion dollars. The total debt was around 19,3 billion dollars. This is 65,03 percent of the total balance sheet. The American company's price/earnings-ratio was 18. So the market valued the stock at 18 times the 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.
At the end of 2015 the health care company's market capitalization (the number of shares times the market price) equaled around 64,87 billion dollars. At the end of 2015 the American company had around 647,37 million stocks listed.
All the annual reports of Johnson & Johnson are available here. More information about Johnson & Johnson can be found it's website. .
Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Revenue |
70,074
|
71,890
|
76,450
|
81,581
|
82,059
|
82,584
|
Costs |
54,665
|
55,350
|
75,150
|
66,284
|
66,940
|
67,870
|
Profit |
15,409
|
16,540
|
1,300
|
15,297
|
15,119
|
14,714
|
Margin of profit |
21.99
|
23.01
|
1.70
|
18.75
|
18.42
|
17.82
|
ROI |
21.66
|
23.49
|
2.16
|
25.60
|
25.42
|
23.25
|
Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Equity |
71,150
|
70,418
|
60,160
|
59,752
|
59,471
|
63,278
|
Debt |
62,261
|
70,790
|
97,143
|
93,202
|
98,257
|
111,616
|
Total assets |
133,411
|
141,208
|
157,303
|
152,954
|
157,728
|
174,894
|
Solvency |
53.33
|
49.87
|
38.24
|
39.07
|
37.70
|
36.18
|
Cash |
38,376
|
41,907
|
18,296
|
19,687
|
19,287
|
25,185
|
Cashflow |
19,569
|
18,767
|
21,056
|
22,201
|
23,416
|
23,536
|
Employees |
0
|
0
|
0
|
0
|
0
|
|
Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
Cashflow / Debt |
0.31
|
0.27
|
0.22
|
0.24
|
0.24
|
0.21
|
Details |
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|
Price |
102.72
|
115.21
|
139.72
|
129.05
|
145.87
|
Eps |
5.93
|
0.47
|
5.61
|
5.63
|
5.51
|
Price/earnings-ratio |
17.32
|
245.13
|
24.91
|
22.92
|
26.11
|
Dividend |
3.15
|
3.32
|
3.54
|
3.75
|
3.98
|
Dividend % |
3.07 %
|
2.88 %
|
2.53 %
|
2.91 %
|
2.77 %
|
Payout % |
0.53
|
7.06
|
0.63
|
0.67
|
0.72
|
Book value |
26.02
|
22.43
|
22.44
|
22.59
|
24.04
|
Market to book |
0.25
|
0.19
|
0.16
|
0.18
|
0.17
|
Cashflow per stock |
6.93
|
7.85
|
8.34
|
8.89
|
8.94
|
Stocks |
2,707
|
2,683
|
2,662
|
2,633
|
2,633
|
Market Cap |
278.012.81
|
309.053.71
|
371.979.35
|
339.725.42
|
378.686.56
|
Date
|
Price
|
---|---|
17 Dec 2024
|
143.85
|
10 Dec 2024
|
149.60
|
06 Dec 2024
|
149.52
|
03 Dec 2024
|
154.80
|
29 Nov 2024
|
155.40
|
27 Nov 2024
|
154.52
|
13 Nov 2024
|
152.64
|
08 Nov 2024
|
156.73
|
05 Nov 2024
|
158.24
|
31 Oct 2024
|
160.61
|
29 Oct 2024
|
161.60
|
23 Oct 2024
|
163.45
|
19 Oct 2024
|
165.12
|
16 Oct 2024
|
164.10
|
14 Oct 2024
|
161.46
|
05 Oct 2024
|
160.29
|
02 Oct 2024
|
161.99
|
27 Sep 2024
|
161.39
|
20 Sep 2024
|
164.82
|
17 Sep 2024
|
166.99
|
13 Sep 2024
|
164.64
|
28 Aug 2024
|
162.95
|
26 Aug 2024
|
164.13
|
23 Aug 2024
|
162.35
|
11 Aug 2024
|
160.62
|
07 Aug 2024
|
158.90
|
05 Aug 2024
|
164.14
|
01 Aug 2024
|
157.85
|
30 Jul 2024
|
158.56
|
26 Jul 2024
|
159.64
|